RU2010133847A - Терапевтические ингибиторы функции pai-1 и способы их применения - Google Patents

Терапевтические ингибиторы функции pai-1 и способы их применения Download PDF

Info

Publication number
RU2010133847A
RU2010133847A RU2010133847/10A RU2010133847A RU2010133847A RU 2010133847 A RU2010133847 A RU 2010133847A RU 2010133847/10 A RU2010133847/10 A RU 2010133847/10A RU 2010133847 A RU2010133847 A RU 2010133847A RU 2010133847 A RU2010133847 A RU 2010133847A
Authority
RU
Russia
Prior art keywords
amino acid
acid residues
acid residue
peptide
seq
Prior art date
Application number
RU2010133847/10A
Other languages
English (en)
Russian (ru)
Inventor
Томас Д. РИД (US)
Томас Д. РИД
Ричард И. ПЕТЕРСОН (US)
Ричард И. ПЕТЕРСОН
Чарльз С. РИД (US)
Чарльз С. РИД
СОПЧИНСКИ Джоан МАЗЗАРЕЛЛИ (US)
СОПЧИНСКИ Джоан МАЗЗАРЕЛЛИ
Бетани Л. МЕРЕНИК (US)
Бетани Л. МЕРЕНИК
Джонатан КАРСОН (US)
Джонатан КАРСОН
Кэтрин Л. БЭИР (US)
Кэтрин Л. БЭИР
Елена ТАШЕВА (US)
Елена ТАШЕВА
Original Assignee
Интрексон Корпорейшн (Us)
Интрексон Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интрексон Корпорейшн (Us), Интрексон Корпорейшн filed Critical Интрексон Корпорейшн (Us)
Publication of RU2010133847A publication Critical patent/RU2010133847A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2451—Glucanases acting on alpha-1,6-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01099—Arabinan endo-1,5-alpha-L-arabinosidase (3.2.1.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2010133847/10A 2008-01-09 2009-01-09 Терапевтические ингибиторы функции pai-1 и способы их применения RU2010133847A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2013708P 2008-01-09 2008-01-09
US61/020,137 2008-01-09
US8064008P 2008-07-14 2008-07-14
US61/080,640 2008-07-14

Publications (1)

Publication Number Publication Date
RU2010133847A true RU2010133847A (ru) 2012-05-20

Family

ID=40853701

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010133847/10A RU2010133847A (ru) 2008-01-09 2009-01-09 Терапевтические ингибиторы функции pai-1 и способы их применения

Country Status (12)

Country Link
US (2) US8431363B2 (enExample)
EP (1) EP2242501A4 (enExample)
JP (2) JP2011509093A (enExample)
KR (1) KR101712208B1 (enExample)
CN (1) CN102123721A (enExample)
AU (1) AU2009204464B2 (enExample)
BR (1) BRPI0906867A2 (enExample)
CA (1) CA2711878A1 (enExample)
IL (1) IL206891A0 (enExample)
MX (1) MX2010007586A (enExample)
RU (1) RU2010133847A (enExample)
WO (1) WO2009089059A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089059A2 (en) 2008-01-09 2009-07-16 Intrexon Corporation Therapeutic inhibitors of pai-1 function methods of their use
WO2011143499A1 (en) * 2010-05-12 2011-11-17 Tengion, Inc. Bioactive renal cells
WO2013164970A1 (ja) 2012-05-01 2013-11-07 富士フイルム株式会社 多能性幹細胞の培養方法及びこれに用いるポリペプチド
CN103421781B (zh) * 2012-07-04 2014-12-31 华中农业大学 猪肌肉组织特异性表达基因myf6启动子及应用
WO2015086548A1 (en) * 2013-12-10 2015-06-18 F. Hoffmann-La Roche Ag Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
TW201822809A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療高脂血症的方法
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
EP3902913A1 (en) 2018-12-28 2021-11-03 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
CN119656313A (zh) * 2024-12-13 2025-03-21 四川大学华西医院 Serpine1基因作为靶点在制备预防或治疗心肌纤维化药物中的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
AU1191001A (en) * 1999-10-07 2001-05-10 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
DE10053251A1 (de) * 2000-10-26 2002-05-08 Boehringer Ingelheim Pharma Epitope von PAI-1
US20030211095A1 (en) * 2002-05-08 2003-11-13 Abd. Al-Roof Higazi Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
US20030199463A1 (en) 2002-04-23 2003-10-23 Silviu Itescu DNA enzyme to inhibit plasminogen activator inhibitor-1
US20040043026A1 (en) * 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
US7785871B2 (en) * 2002-10-09 2010-08-31 Intrexon Corporation DNA cloning vector plasmids and methods for their use
US20080050808A1 (en) * 2002-10-09 2008-02-28 Reed Thomas D DNA modular cloning vector plasmids and methods for their use
US7071295B2 (en) * 2002-12-02 2006-07-04 Intrexon Corporation Signal for targeting molecules to the sarco(endo)plasmic reticulum
CA2509222A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2005248371B2 (en) 2004-05-18 2011-12-15 Intrexon Corporation Methods for dynamic vector assembly of DNA cloning vector plasmids
US8153598B2 (en) 2005-10-19 2012-04-10 Intrexon Corporation PKD ligands and polynucleotides encoding PKD ligands
WO2007048103A2 (en) 2006-10-18 2007-04-26 Intrexon Corporation Pkd ligands and polynucleotides encoding pkd ligands
US7943732B2 (en) * 2006-06-05 2011-05-17 Intrexon Corporation AKT ligands and polynucleotides encoding AKT ligands
US8993263B2 (en) * 2006-08-07 2015-03-31 Intrexon Corporation PKA ligands and polynucleotides encoding PKA ligands
US8999666B2 (en) * 2006-08-09 2015-04-07 Intrexon Corporation PKC ligands and polynucleotides encoding PKC ligands
US8729225B2 (en) * 2006-11-13 2014-05-20 Intrexon Corporation Glycogen synthase kinase heteropolyligand polypeptide
US8283445B2 (en) * 2006-11-13 2012-10-09 Intrexon Corporation Extracellular-signal-regulated-kinase (ERK) heteropolyligand polypeptide
US7705122B2 (en) * 2006-12-04 2010-04-27 Intrexon Corporation mTOR ligands and polynucleotides encoding mTOR ligands
CN101679956A (zh) * 2007-03-27 2010-03-24 英特拉克森公司 Mek配体和编码mek配体的多核苷酸
WO2009014564A2 (en) 2007-04-27 2009-01-29 The University Of Toledo Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
WO2009089059A2 (en) 2008-01-09 2009-07-16 Intrexon Corporation Therapeutic inhibitors of pai-1 function methods of their use

Also Published As

Publication number Publication date
US20110055940A1 (en) 2011-03-03
AU2009204464A1 (en) 2009-07-16
EP2242501A4 (en) 2011-10-19
EP2242501A2 (en) 2010-10-27
US20130267022A1 (en) 2013-10-10
JP2011509093A (ja) 2011-03-24
JP2012135307A (ja) 2012-07-19
CN102123721A (zh) 2011-07-13
US8828686B2 (en) 2014-09-09
AU2009204464B2 (en) 2014-12-04
WO2009089059A3 (en) 2009-09-24
US8431363B2 (en) 2013-04-30
KR101712208B1 (ko) 2017-03-03
BRPI0906867A2 (pt) 2019-09-24
CA2711878A1 (en) 2009-07-16
MX2010007586A (es) 2011-02-22
IL206891A0 (en) 2010-12-30
KR20100129271A (ko) 2010-12-08
WO2009089059A2 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
RU2010133847A (ru) Терапевтические ингибиторы функции pai-1 и способы их применения
Rucker et al. Elastin metabolism and chemistry: potential roles in lung development and structure
Seki et al. Broiler chickens (Ross strain) lack insulin-responsive glucose transporter GLUT4 and have GLUT8 cDNA
Page Hemokinins and endokinins
Csiszar Lysyl oxidases: a novel multifunctional amine oxidase family
Chiquet-Ehrismann et al. Tenascins and the importance of adhesion modulation
Griendling et al. Molecular biology of the renin-angiotensin system.
Richards Genetic regulation of feed intake and energy balance in poultry
Massagué et al. The TGF-β family and its composite receptors
Bicknell The tissue‐specific processing of pro‐opiomelanocortin
Karam et al. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats: comparison with angiotensin-converting enzyme inhibition and calcium antagonism
Darras et al. Growth hormone acutely decreases type III iodothyronine deiodinase in chicken liver
JP2011509093A5 (enExample)
Rosenbloom [9] Elastin: an overview
Sánchez-Margalet et al. Reprint of: Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin
Hahn et al. Peptide vasoconstrictors, vessel structure, and vascular smooth-muscle proliferation
EP1030916A2 (en) Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis
Tumselty et al. Adipocyte enhancer binding protein 1 and aortic carboxypeptidase-like protein
Huang et al. Cloning of porcine chemerin, ChemR23 and GPR1 and their involvement in regulation of lipogenesis
He et al. Overexpression of Krueppel like factor 3 promotes subcutaneous adipocytes differentiation in goat Capra hircus
Rovero et al. Structure‐activity studies on endothelin (16–21), the C‐terminal hexapeptide of the endothelins, in the guinea‐pig bronchus
Kitabgi Neurotensin and neuromedin N are differentially processed from a common precursor by prohormone convertases in tissues and cell lines
Taniguchi et al. Rapid communication: Nucleotide sequence of bovine C/EBPdelta gene.
Zheng et al. Phylogenetic and expression analysis of the angiopoietin-like gene family and their role in lipid metabolism in pigs
Pan et al. Cloning, molecular characterization, and tissue differential expression of connective tissue growth factor (ctgf) of grass carp

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20140811